Structural basis for ineffective T-cell responses to MHC anchor residue-improved “heteroclitic” peptides-Reference-Cited by-同舟云学术

Structural basis for ineffective T-cell responses to MHC anchor residue-improved “heteroclitic” peptides

Published:2014-12-28 Issue:2 Volume:45 Page:584-591
ISSN:0014-2980
Container-title:European Journal of Immunology
language:en
Short-container-title:Eur. J. Immunol.

Author:

Madura Florian¹,Rizkallah Pierre J.¹,Holland Christopher J.¹,Fuller Anna¹,Bulek Anna¹,Godkin Andrew J.¹,Schauenburg Andrea J.¹,Cole David K.¹,Sewell Andrew K.¹

Affiliation:

1. Division of Infection and Immunity; Cardiff University School of Medicine; Heath Park Cardiff UK

Funder

Wellcome Trust

Research Councils UK

Publisher

Wiley

Subject

Immunology,Immunology and Allergy

Reference49 articles.

1. Cancer immunotherapy: moving beyond current vaccines;Rosenberg;Nat. Med.,2004

2. Structural and biophysical determinants of αβ T-cell antigen recognition;Bridgeman;Immunology,2012

3. Interplay between T cell receptor binding kinetics and the level of cognate peptide presented by major histocompatibility complexes governs CD8 +T cell responsiveness;Irving;J. Biol. Chem.,2012

4. Human TCR-binding affinity is governed by MHC class restriction;Cole;J. Immunol.,2007

5. Different affinity windows for virus and cancer-specific T-cell receptors: implications for therapeutic strategies;Aleksic;Eur. J. Immunol.,2012

Cited by 61 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Old concepts, new tricks: How peptide vaccines are reshaping cancer immunotherapy?;International Journal of Biological Macromolecules;2024-09

2. A Mimicry-Based Strategy Between Human and Commensal Antigens for the Development of a New Family of Immune Therapies for Cancer;2024-06-01

3. PANDORA v2.0: Benchmarking peptide-MHC II models and software improvements;Frontiers in Immunology;2023-12-08

4. Signaling via a CD28/CD40 chimeric costimulatory antigen receptor (CoStAR™), targeting folate receptor alpha, enhances T cell activity and augments tumor reactivity of tumor infiltrating lymphocytes;Frontiers in Immunology;2023-11-07

5. Peptide-based vaccine for cancer therapies;Frontiers in Immunology;2023-08-16